ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.10
-0.99 (-2.10%)
At close: 4:00PM EDT

46.39 +0.29 (0.63%)
After hours: 4:18PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close47.09
Open47.70
Bid45.80 x 1000
Ask46.39 x 800
Day's Range45.86 - 49.00
52 Week Range44.50 - 125.00
Volume1,935,264
Avg. Volume903,595
Market Cap1.519B
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-10.74
Earnings DateAug 05, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
    ACCESSWIRE

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / July 2, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, ...

  • FDA Rejects Intercept’s Liver Disease Drug, But This Analyst Still Anticipates Approval
    TipRanks

    FDA Rejects Intercept’s Liver Disease Drug, But This Analyst Still Anticipates Approval

    No pain, no gain goes the well-worn axiom. A stock market themed inverse can read: no gain, shareholder pain. You can currently apply the latter to Intercept Pharmaceuticals (ICPT). The small-cap biotech was hoping to gain the FDA’s nod of approval for its liver disease therapy, but there was only pain to endure, as the NDA was rejected. As a result, shares were sent tumbling by 40% on Monday June 29. So, what happened exactly? ICPT received a CRL from the FDA regarding its obeticholic acid (OCA) treatment in advanced-stage non-alcoholic steatohepatitis (NASH), due to a lack of evidence showing that the benefits of the treatment outweigh the potential risks. The FDA recommended that data from the ongoing Phase 3 REGENERATE study be further analyzed. NASH is a fatty liver disease, closely related to obesity, for which there are currently no specific drugs available. Due to the rising obesity rates, the market for NASH medications is expected to grow considerably over the next few years, with some estimates putting its worth at $35 billion. Intercept’s application was based on data from the treatment of over 1,700 NASH patients across 35 clinical trials. Management expects to schedule a meeting with the FDA in 2H20 to discuss how to move forward. Needham analyst Alan Carr expects the NDA to be resubmitted before the end of the year, and anticipates “the drug will be approved in the U.S. by mid-2021.” The analyst believes the rejection might have more to do with the current macro climate than with the data itself. Carr said, “We acknowledge the FDA clearly has some level of concern w/ OCA, however, we believe COVID-19 has played a role in disrupting and preventing completion of the review process. We await the outcome of the meeting with the FDA and assume resubmission by YE20. We still believe OCA will be approved in NASH, but have reduced our target due to launch delay.” That price target is slashed from $150 to $100, although the figure still implies hefty upside potential of 115%. Carr made no change to the rating, which remains a Buy. (To watch Carr’s track record, click here) Looking at the consensus breakdown, based on 6 Buys and 15 Holds, ICPT has a Moderate Buy consensus rating. With an average price target of $66.10, the analysts forecast possible upside of 42% over the next 12 months. (See Intercept price targets and analyst ratings on TipRanks)

  • SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
    ACCESSWIRE

    SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / July 1, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, ...

  • Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
    Zacks

    Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More

    The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.

  • Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback?
    Motley Fool

    Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback?

    Intercept Pharmaceuticals (NASDAQ: ICPT) fully expected approval from the Food and Drug Administration for obeticholic acid (OCA) in treating non-alcoholic steatohepatitis (NASH). CEO Mark Pruzanski even stated on the company's Q1 conference call last month that the drugmaker would be "prepared to launch as soon as possible" after that anticipated approval.

  • Barrons.com

    Intercept Shares Tumble on NASH Disappointment

    NASH was once the next big thing for big pharma; a newly defined disorder requiring chronic treatment afflicting millions of people in developed countries. In May, a French company called (GNFT)(ticker: GNFT), which had one of the most advanced NASH programs, announced that a Phase 3 trial of its NASH drug Elafinbranor had failed to achieve its primary endpoint. Now, another setback is tanking shares of (ICPT)(ICPT), which analysts had expected to introduce the first NASH drug sometime this year.

  • The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)
    Business Wire

    The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)

    The Law Offices of Frank R. Cruz announces an investigation on behalf of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) investors concerning the Company and its officers’ possible violations of federal securities laws.

  • Business Wire

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors

  • ACCESSWIRE

    ICPT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intercept Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intercept Pharmaceuticals, Inc. ("Intercept" or "the ...

  • TheStreet.com

    Intercept Stock Off - FDA Declines to Clear Liver-Disease Drug

    Intercept Pharmaceuticals shares fell after the FDA declined to clear its drug for a progressive liver disease.

  • Reuters

    U.S. FDA declines to approve Intercept's chronic liver disease therapy

    The FDA has sought additional post-interim analysis data from an ongoing late-stage trial in support of the marketing application as it found predicted effectiveness of the treatment failed to outweigh its potential risks. The therapy, chemically known as obeticholic acid, is designed to improve fibrosis, or the build up of scar tissue in the liver caused by non-alcoholic steatohepatitis (NASH), a chronic disease related to obesity. Intercept said the FDA's decision was premature and disagreed with the denial of approval based on the treatment's effectiveness.

  • MarketWatch

    Intercept Pharmaceuticals receives FDA Complete Response Letter for treatment for fibrosis due to NASH

    Intercept Pharmaceuticals Inc. shares tumbled more than 30% in premarket trade Monday, after the company said it has received a U.S. Food and Drug Administration Complete Response Letter regarding its New Drug Application for a treatment for fibrosis caused by nonalcoholic steatohepatitis, or NASH. The letter says that based on the data the regulator has reviewed to date, the predicted benefit of the treatment, obeticholic acid, or OCA, is uncertain and does not sufficiently outweigh the potential risks to support accelerated approval. "The FDA recommends that Intercept submit additional post-interim analysis efficacy and safety data from the ongoing REGENERATE study in support of potential accelerated approval and that the long-term outcomes phase of the study should continue," the company said in a statement. Intercept Chief Executive Mark Pruzanski said he was disappointed by the FDA decision, which is "based on an apparently incomplete review, and without having provided medical experts and patients the opportunity to be heard at the anticipated Adcom on the merits of OCA, which is a designated Breakthrough Therapy." The FDA has "progressively increased the complexity of the histologic endpoints, creating a very high bar that only OCA has so far met in a pivotal Phase 3 study," he said. The company will seek a meeting with the FDA and will hold a conference call with investors at 8.30 a.m. Eastern Time. Shares have fallen 37% in the year through Friday, while the S&P 500 has fallen 7%.

  • GlobeNewswire

    Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH

    Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH). The CRL indicated that, based on the data the FDA has reviewed to date, the Agency has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH.

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For June 25, 2020

    Upgrades * Credit Suisse changed the rating for Allstate Corp (NYSE: ALL) from Underperform to Neutral. Allstate earned $3.54 in the first quarter, compared to $2.30 in the year-ago quarter. The stock has a 52-week-high of $125.92 and a 52-week-low of $64.13. Allstate's stock last closed at $92.96 per share. * SunTrust Robinson Humphrey upgraded the stock for Diamondback Energy Inc (NASDAQ: FANG) from Hold to Buy. For the first quarter, Diamondback Energy had an EPS of $1.45, compared to year-ago quarter EPS of $1.39. The stock has a 52-week-high of $111.84 and a 52-week-low of $14.55. Diamondback Energy's stock last closed at $41.90 per share. * Goldman Sachs changed the rating for Ameriprise Financial Inc (NYSE: AMP) from Neutral to Buy. For the first quarter, Ameriprise Financial had an EPS of $5.41, compared to year-ago quarter EPS of $3.75. The stock has a 52-week-high of $180.85 and a 52-week-low of $80.01. Ameriprise Financial's stock last closed at $142.90 per share. * Stifel upgraded the stock for AeroVironment Inc (NASDAQ: AVAV) from Hold to Buy. AeroVironment earned $0.75 in the fourth quarter, compared to $0.26 in the year-ago quarter. The stock has a 52-week-high of $79.54 and a 52-week-low of $45.00. AeroVironment's stock last closed at $71.80 per share. * Baird changed the rating for Fortive Corp (NYSE: FTV) from Neutral to Outperform. For the first quarter, Fortive had an EPS of $0.74, compared to year-ago quarter EPS of $0.69. The stock has a 52-week-high of $83.18 and a 52-week-low of $37.31. Fortive's stock last closed at $66.02 per share. * Goldman Sachs upgraded the stock for Patterson Companies Inc (NASDAQ: PDCO) from Sell to Neutral. Patterson Companies earned $0.43 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $25.70 and a 52-week-low of $12.93. Patterson Companies's stock last closed at $20.03 per share. Downgrades * Oppenheimer changed the rating for iQIYI Inc (NASDAQ: IQ) from Outperform to Perform. In the first quarter, iQIYI showed an EPS of ($0.56), compared to ($0.35) from the year-ago quarter. The stock has a 52-week-high of $27.50 and a 52-week-low of $14.51. iQIYI's stock last closed at $22.92 per share. * Berenberg changed the rating for Boeing Co (NYSE: BA) from Hold to Sell. For the first quarter, Boeing had an EPS of ($1.70), compared to year-ago quarter EPS of $3.16. The stock has a 52-week-high of $391.00 and a 52-week-low of $89.00. Boeing's stock last closed at $176.79 per share. * BMO Capital downgraded the stock for Century Aluminum Co (NASDAQ: CENX) from Outperform to Market Perform. Century Aluminum earned $0.01 in the first quarter, compared to ($0.70) in the year-ago quarter. The stock has a 52-week-high of $8.42 and a 52-week-low of $2.91. Century Aluminum's stock last closed at $6.91 per share. * For GrubHub Inc (NYSE: GRUB), Canaccord Genuity downgraded the stock from Buy to Hold. In the first quarter, GrubHub showed an EPS of $0.00, compared to $0.30 from the year-ago quarter. The stock has a 52-week-high of $80.25 and a 52-week-low of $29.35. GrubHub's stock last closed at $68.36 per share. * Wells Fargo changed the rating for Marathon Oil Corp (NYSE: MRO) from Overweight to Equal-Weight. Marathon Oil earned ($0.16) in the first quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $14.70 and a 52-week-low of $3.02. Marathon Oil's stock last closed at $5.78 per share. * Wells Fargo changed the rating for uniQure NV (NASDAQ: QURE) from Overweight to Equal-Weight. For the first quarter, uniQure had an EPS of ($0.63), compared to year-ago quarter EPS of ($0.74). The stock has a 52-week-high of $79.97 and a 52-week-low of $36.20. uniQure's stock last closed at $62.91 per share. * Goldman Sachs downgraded the stock for SolarEdge Technologies Inc (NASDAQ: SEDG) from Neutral to Sell. In the first quarter, SolarEdge Technologies showed an EPS of $0.95, compared to $0.64 from the year-ago quarter. The stock has a 52-week-high of $156.92 and a 52-week-low of $58.84. SolarEdge Technologies's stock last closed at $148.48 per share. * For Vivint Solar Inc (NYSE: VSLR), Goldman Sachs downgraded the stock from Buy to Neutral. For the first quarter, Vivint Solar had an EPS of ($0.32), compared to year-ago quarter EPS of ($0.22). The stock has a 52-week-high of $12.99 and a 52-week-low of $3.17. Vivint Solar's stock last closed at $10.04 per share. Initiations * B of A Securities initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO) with a Neutral rating. The price target for BridgeBio Pharma is set at $38.00. In the first quarter, BridgeBio Pharma showed an EPS of ($0.78), compared to ($0.66) from the year-ago quarter. The stock has a 52-week-high of $48.36 and a 52-week-low of $14.23. BridgeBio Pharma's stock last closed at $32.96 per share. * With a rating of Buy, B of A Securities initiated coverage on NeoGenomics Inc (NASDAQ: NEO). The price target is set at $34.00 for NeoGenomics. In the first quarter, NeoGenomics showed an EPS of ($0.02), compared to $0.07 from the year-ago quarter. The stock has a 52-week-high of $34.97 and a 52-week-low of $18.52. NeoGenomics's stock last closed at $27.78 per share. * B of A Securities initiated coverage on Athersys Inc (NASDAQ: ATHX) with a Buy rating. The price target for Athersys is set at $5.00. In the first quarter, Athersys showed an EPS of ($0.10), compared to ($0.09) from the year-ago quarter. The stock has a 52-week-high of $4.38 and a 52-week-low of $1.13. Athersys's stock last closed at $2.22 per share. * Berenberg initiated coverage on Splunk Inc (NASDAQ: SPLK) with a Buy rating. The price target for Splunk is set at $222.00. For the first quarter, Splunk had an EPS of ($0.56), compared to year-ago quarter EPS of $0.02. The stock has a 52-week-high of $197.22 and a 52-week-low of $93.92. Splunk's stock last closed at $190.61 per share. * HC Wainwright & Co. initiated coverage on Intercept Pharmaceuticals Inc (NASDAQ: ICPT) with a Neutral rating. The price target for Intercept Pharmaceuticals is set at $92.00. For the first quarter, Intercept Pharmaceuticals had an EPS of ($2.86), compared to year-ago quarter EPS of ($3.03). The stock has a 52-week-high of $125.00 and a 52-week-low of $47.57. Intercept Pharmaceuticals's stock last closed at $78.16 per share. * With a rating of Buy, HC Wainwright & Co. initiated coverage on Flexion Therapeutics Inc (NASDAQ: FLXN). The price target is set at $25.00 for Flexion Therapeutics. In the first quarter, Flexion Therapeutics showed an EPS of ($0.95), compared to ($1.09) from the year-ago quarter. The stock has a 52-week-high of $22.98 and a 52-week-low of $5.01. Flexion Therapeutics's stock last closed at $12.09 per share. * With a rating of Outperform, Oppenheimer initiated coverage on DocuSign Inc (NASDAQ: DOCU). The price target is set at $200.00 for DocuSign. For the first quarter, DocuSign had an EPS of $0.12, compared to year-ago quarter EPS of $0.07. The stock has a 52-week-high of $172.21 and a 52-week-low of $43.13. DocuSign's stock last closed at $163.91 per share. * With a rating of Outperform, SMBC Nikko initiated coverage on Inphi Corp (NYSE: IPHI). The price target is set at $140.00 for Inphi. Inphi earned $0.62 in the first quarter, compared to $0.33 in the year-ago quarter. The stock has a 52-week-high of $127.78 and a 52-week-low of $48.30. Inphi's stock last closed at $109.23 per share. * With a rating of Buy, B. Riley FBR initiated coverage on Medifast Inc (NYSE: MED). The price target is set at $164.00 for Medifast. In the first quarter, Medifast showed an EPS of $1.93, compared to $1.70 from the year-ago quarter. The stock has a 52-week-high of $130.99 and a 52-week-low of $49.03. Medifast's stock last closed at $122.94 per share. * Wells Fargo initiated coverage on MKS Instruments Inc (NASDAQ: MKSI) with a Equal-Weight rating. The price target for MKS Instruments is set at $120.00. For the first quarter, MKS Instruments had an EPS of $1.54, compared to year-ago quarter EPS of $1.12. The stock has a 52-week-high of $122.30 and a 52-week-low of $66.87. MKS Instruments's stock last closed at $112.83 per share. * Wells Fargo initiated coverage on Range Resources Corp (NYSE: RRC) with a Equal-Weight rating. The price target for Range Resources is set at $11.00. For the first quarter, Range Resources had an EPS of $0.04, compared to year-ago quarter EPS of $0.36. The stock has a 52-week-high of $8.25 and a 52-week-low of $1.61. Range Resources's stock last closed at $5.59 per share. * Stephens & Co. initiated coverage on SmileDirectClub Inc (NASDAQ: SDC) with an Overweight rating. The price target for SmileDirectClub is set at $11.00. Interestingly, in the first quarter, SmileDirectClub's EPS was ($0.28). The stock has a 52-week-high of $21.10 and a 52-week-low of $3.64. SmileDirectClub's stock last closed at $7.14 per share. * Baird initiated coverage on Albireo Pharma Inc (NASDAQ: ALBO) with an Outperform rating. The price target for Albireo Pharma is set at $52.00. In the first quarter, Albireo Pharma showed an EPS of ($2.23), compared to ($1.39) from the year-ago quarter. The stock has a 52-week-high of $32.49 and a 52-week-low of $11.26. Albireo Pharma's stock last closed at $26.61 per share. * With a rating of Buy, MKM Partners initiated coverage on Talos Energy Inc (NYSE: TALO). The price target is set at $17.00 for Talos Energy. Talos Energy earned $0.27 in the first quarter, compared to $0.19 in the year-ago quarter. The stock has a 52-week-high of $31.34 and a 52-week-low of $5.00. Talos Energy's stock last closed at $9.15 per share.See more from Benzinga * Enerpac Tool Group: Q3 Earnings Insights * 10 Technology Stocks Moving In Thursday's Pre-Market Session * 11 Energy Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is Intercept Pharmaceuticals Inc (ICPT) Going to Burn These Hedge Funds?
    Insider Monkey

    Is Intercept Pharmaceuticals Inc (ICPT) Going to Burn These Hedge Funds?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT

    NEW YORK, NY / ACCESSWIRE / June 17, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (ICPT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intercept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Is Intercept Pharmaceuticals Stock a Buy?
    Motley Fool

    Is Intercept Pharmaceuticals Stock a Buy?

    Here's why this leader in treating progressive non-viral liver disease is, in fact, a solid buy.

  • Many 'Ifs' Surrounding Viking Therapeutics
    GuruFocus.com

    Many 'Ifs' Surrounding Viking Therapeutics

    The company needs to get liver disease drug approved and find help to commercialize it Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of ICPT earnings conference call or presentation 11-May-20 12:30pm GMT

    Q1 2020 Intercept Pharmaceuticals Inc Earnings Call

  • Why Is Intercept (ICPT) Down 9.4% Since Last Earnings Report?
    Zacks

    Why Is Intercept (ICPT) Down 9.4% Since Last Earnings Report?

    Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.